What's holding back biotech M&A? SVB tracks a trend and calls a comeback
The dealmakers in biopharma have had some extra time on their hands in the first half of 2017. M&A has slowed considerably, but one prominent …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
